Member Info for silverhorse

Hi cashintime - Do you hold more then Jeremy Skillington ?

6.60 is my new buy target for the rest of the year this will go slow - After looking at it hitting 7.70 again falling back i dumped 7.67.

Poolbeg Pharma PLC chief executive Jeremy Skillington speaks to Proactive after researchers identified "multiple" potential drug targets for respiratory syncytial virus (RSV) using artificial intelligence. AI technology developed by OneThree Biotech was used to "interrogate" the large bank of RSV human challenge data held by Poolbeg.

Skillington says that the breakthrough makes this a "very exciting time for the company" and expects the collaboration to continue bearing fruit, particularly because RSV is "rampant" and affects "up to 50mln people a year."

This share is like the good the bad or ugly - we all know good wins

Agree - You would think the share price would jump up 7.70 for sure - smash the 8euros this week - lets see

Hotchip -POLB001 will be very positive lets make that clear!

All our assets are worth more then 1p so not that bad

RNS would be very helpful - if they really care about us - only good thing we are same price again 1/2 a penny -

Hi PC -Still above our target - likely have a sharp run over 8euros this week - u agree?

U ok huld?

I was never a fan trading this stock - we all know 2023 will be a super year for bank of ireland

Hi PC - I bet you did not expect to see the share price spike to 7.682 this morning - i was 50/50 it would happen - at 12 it will shoot up again

Roderick is cutting of the fat to get a very juicy steak

torquay - If you have some funds buy POLB under 7p its will be over 10p and alot more very very soon for certain.

Its will go up more for sure playcards - 7.50 seems to low at the moment

Including that it is in constant discussions with other pharma and biotech companies about in-licensing, out-licensing and other deals as it aims to become a 'one-stop shop' for infectious disease drugs.Once data is received from the POLB 001 study in the second half of 2022, the company said it will look to secure ways of monetising the asset via licensing or partnership agreements with pharma and biotech companies, a key process in its asset-light business model.

Expect some larger buys rest of this week - under 7p likely last - News soon - including preliminary outputs in the second half of the year from the artificial intelligence discovery programme for respiratory syncytial virus (RSV), as part of the deal struck with OneThree Biotech. Poolbeg said it is currently evaluating opportunities for non-dilutive grant funding to support the development of its pipeline - POLB 003 .

Its a done deal now -

Its very clear the share price will go well over 1p again - lets keep this quiet and keep buying

The Munni Munni Project is considered to be one of Australia’s largest PGE deposits with in excess of A$20m spent on various feasibility studies undertaken in the last 20 plus years. Previous project joint venture partners include one of South Africa’s largest platinum palladium producers, Lonmin.